Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiation OncologyCareFirst Gamma‑ray SRS Coverage Update | OpenPaye…
    Ask Trek AI about this page
    RetiredCareFirstPolicy 6.01.043

    Stereotactic Radiosurgery Using Gamma Rays

    Customize your policy alerts

    Sign up for CareFirst Policy 6.01.043 alerts

    Get alerted when Policy 6.01.043 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and investigational uses of stereotactic radiosurgery using cobalt-60 gamma rays (e.g., Gamma Knife®) for intracranial and select extra‑cranial indications and governs CareFirst coverage for affected members and providers.

    Policy Summary
    PayerCareFirst
    PolicyStereotactic Radiosurgery Using Gamma Rays
    Policy CodePolicy 6.01.043
    Change TypeRetiredadopted external MCG criteria
    Effective DateFeb 1, 2026
    Last ReviewNov 12, 2025
    Next Review DateNov 12, 2025
    Key ActionSubmit preauthorization requests online at www.provider.carefirst.com or call 1-866-773-2884 and verify member contract and prior authorization requirements.
    SourceLink
    POLICY UPDATE CHANGES

    CareFirst has adopted the position of MCG Care Guidelines® and retired this policy, directing readers to the MCG site for medical necessity criteria.

    The medically necessary indications were revised in 2023 to add epilepsy and to broaden the experimental/investigational statement to 'all other uses' rather than calling out chronic pain specifically.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ~12Medically necessary indications listed
    RETIREDPolicy status
    ECOG/KPSPerformance status requirements cited
    MCGAdopted external criteria
    1Related policy cross-reference

    Coverage and Medical Necessity Criteria

    Medically necessary indications

    Gamma-ray stereotactic radiosurgery (e.g., Gamma Knife®) is considered medically necessary for any one of the following indications:

    • Vascular malformation: Angiographically visible arteriovenous malformations (AVM)
    • Benign cranial tumors: Initial or recurrent benign cranial tumors including acoustic neuromas (smaller than 3 cm), non-resectable/residual/recurrent meningioma, and pituitary adenoma (e.g., Cushing's disease or acromegaly)
    • Brain metastases: Solitary or multiple brain metastases in individuals with good performance status, defined by ALL of the following where applicable: absence of a large tumor (e.g., ~3.5 cm) on diagnostic imaging; ECOG ≤ 3 and expected to return to ≤ 2 with treatment; Karnofsky > 40 and expected to return to ≥ 70 with treatment

      Performance status and tumor size criteria referenced in policy (see performance scales)

    • Primary malignant brain neoplasms: Primary malignant neoplasms of the brain, initial or recurrent, without mass effect (e.g., no midline shift) on diagnostic imaging
    • Epilepsy when ALL of the following are met: brain MRI findings concordant with EEG findings; EEG demonstrates a localized epileptogenic source (e.g., mesial temporal lobe); seizures refractory to at least two different anticonvulsant medications
    • Essential tremor when ALL of the following are met: deep brain stimulation is not an option; disability of one or more limbs from resting, positional, or kinetic tremor that affects safety, functional status, or quality of life; tremor refractory to one year or more of standard medication
    • Glomus jugulare tumor when ONE or more of the following apply: contraindication to microsurgical resection (e.g., unacceptable operative risk or tumor adjacent to critical structures); residual or recurrent tumor following microsurgical resection
    • Trigeminal neuralgia refractory to medical management
    • Non-operable spinal tumor (primary, recurrent, or metastatic) that is causing compression or intractable pain
    • Uveal tract melanoma (melanoma of the iris, ciliary body, or choroid)

    Experimental / Investigational

    All other uses of gamma-ray stereotactic radiosurgery are considered experimental/investigational because the TEC/BCBSA evidentiary criteria are not met.

    Investigational uses: Any use of gamma-ray SRS not listed in the medically necessary indications is considered experimental/investigational.

    Rationale: available evidence does not permit conclusions about net health benefit for other indications (insufficient quantity/quality of studies, heterogeneous methods, small sample sizes, limited follow-up).

    General clinical eligibility considerations

    General clinical eligibility and administrative considerations to establish medical necessity and process requests:

    Functional status assessment: Assess and document functional status using ECOG or Karnofsky performance scales; treatment candidacy should consider whether improvement is attainable outside investigational settings.ECOG 0–5 and Karnofsky 0–100 described in policy

    Exact numeric cutoffs for specific indications are provided in individual indication nodes (e.g., brain metastases). Document expected post-treatment functional improvement when referenced.

    Prior authorization and benefit verification: Verify member contract benefits, place-of-service rules, and whether prior authorization is required; follow facility and contractual requirements for inpatient/outpatient services.

    Providers must check member contract and submit preauthorization requests as required (see provider guidelines).

    Required documentation: Include imaging (CT/MRI/angiography) demonstrating target localization, performance status (ECOG and/or Karnofsky), and a multidisciplinary treatment plan in the medical record and authorization request.

    This policy specifically addresses stereotactic radiosurgery (SRS) delivered with cobalt-60 gamma rays (e.g., Gamma Knife®). It does not address SRS or SBRT delivered with photons or linear accelerators; those techniques are covered under the CareFirst policy “Stereotactic Radiosurgery and Stereotactic Body Radiotherapy with 3‑D Conformal Radiation Therapy (Policy #6.00.010).” In addition, neutron beam, proton beam, and helium ion therapies are governed by separate medical policies and are not covered by this gamma‑ray SRS policy (see Policy 6.01.018 and Policy 6.01.048).

    Coverage for services described in this policy will vary by member contract, line of business, and place of service. Specific contract provisions, restrictions, and exclusions take precedence over the clinical criteria in this policy; always verify the member’s benefit plan before proceeding. Some services and places of service may require prior authorization per contract or facility rules.

    The evidence does not support the use of gamma‑ray SRS for a number of indications. Reported literature limitations (small sample sizes, heterogeneous methods, short follow‑up) mean SRS is considered experimental/investigational for conditions such as chronic pain syndromes (other than trigeminal neuralgia), cluster headaches, facial nerve schwannomas, and psychiatric disorders (e.g., obsessive‑compulsive disorder). Published reviews and series report inconsistent benefit and methodologic concerns; additional well‑designed studies are needed to demonstrate net health benefit.

    Member contract terms may impose additional restrictions that render a service noncovered even if clinical criteria are met. Providers must check the member’s contract and applicable benefit limitations; contract provisions supersede the clinical criteria in this policy and may result in denial or noncoverage.

    Coding and Performance Thresholds

    No explicit CPT/HCPCS/ICD codes listed in this documentmixed
    No codes listed
    Referenced coding resourcemixed
    CPTReferenced: Current Procedural Terminology (CPT) (4th edition) cited as a resource (2010).
    Tumor size and performance thresholds (examples)
    Brain metastases size and performance thresholdsAbsence of large tumor on diagnostic imaging (example: 3.5 cm); ECOG 3 or less with expectation to return to ≤2 after treatment; Karnofsky scale greater than 40 with expectation to return to ≥70 after treatment.
    Acoustic neuroma size thresholdAcoustic neuromas smaller than 3 cm are listed as an indication for gamma‑ray SRS.
    General tumor size exampleExample tumor size threshold cited for eligibility: 3.5 cm (used to define ‘absence of large tumor’ for metastases).
    Karnofsky actionable cutoffKarnofsky >40 (with expectation to return to ≥70) is used as a performance threshold for brain metastases eligibility.
    ECOG actionable cutoffECOG ≤3 (with expectation to return to ≤2) is used as a performance threshold for brain metastases eligibility.

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Some services, devices, drugs, and places of service require prior authorization. Providers must obtain prior authorization when indicated and follow MCG criteria adopted by CareFirst for stereotactic radiosurgery. Check the member contract for benefit specifics, as contract provisions, restrictions, and exclusions take precedence over the clinical criteria.

    • Submit preauthorization requests online at www.provider.carefirst.com
    • Or call 1-866-773-2884 (1-866-PRE-AUTH)
    Denial Risk

    Denial Risk for Non‑listed Indications

    Requests for indications not listed in the policy (including uses that do not meet the adopted MCG criteria) are considered experimental/investigational and are at high risk for denial.

    Background and Scope

    Stereotactic radiosurgery (SRS) is a nonsurgical, highly focused radiation technique that delivers a high dose of radiation to a small, well‑defined target using multiple convergent beams. Gamma‑ray SRS (example: Gamma Knife®) is typically delivered in a single session using stereotactic immobilization, imaging (CT, MRI, or angiography) for target localization, and computerized treatment planning to shape dose and spare adjacent critical structures. An immobilizing frame is often used during treatment to ensure accuracy; once positioned, the patient is monitored from an adjacent control room while beams converge on the treatment target. Functional status scales such as the Karnofsky and ECOG scores are used to assess candidacy and expected outcomes.

    Definitions and Performance Scales

    Definition: stereotactic radiosurgery (gamma rays / Gamma Knife®)
    DefinitionStereotactic radiosurgery (SRS) using gamma rays is a one-session, 3‑dimensional conformal radiation therapy delivered with Cobalt‑60 sources (example: Gamma Knife®) that uses multiple convergent gamma‑ray beams focused on a precisely defined intracranial target.
    Delivery modalitySingle‑session cobalt‑60 based therapy (Gamma Knife®) employing stereotactic immobilization and advanced imaging for precise target localization.
    Multidisciplinary planningTreatment planning and delivery involve a multidisciplinary team including a radiation oncologist, medical physicist, neurosurgeon, dosimetrist, and radiation therapists.
    Performance status scales referenced for candidacy
    Performance status roleECOG and Karnofsky scales are used to assess functional status and candidacy for gamma‑ray SRS.

    Policy Revision History

    2026-02-01Retired/adopted external guidanceLatest

    Policy retired and CareFirst adopted the position of MCG Care Guidelines® for medical necessity and clinical appropriateness of stereotactic radiosurgery; readers directed to the MCG site.

    2025-11-12Annual review and operational update

    Annual update and review documented; policy status updated in association with adoption of MCG Care Guidelines® and retirement of the policy.

    2023
    Policy Summary
    PayerCareFirst
    PolicyStereotactic Radiosurgery Using Gamma Rays
    Policy CodePolicy 6.01.043
    Change TypeRetiredadopted external MCG criteria
    Effective DateFeb 1, 2026
    Last ReviewNov 12, 2025
    Next Review DateNov 12, 2025
    Key ActionSubmit preauthorization requests online at www.provider.carefirst.com or call 1-866-773-2884 and verify member contract and prior authorization requirements.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCoding and Performance ThresholdsProvider Actions, Prior Authorization, and DocumentationBackground and ScopeDefinitions and Performance ScalesPolicy Revision History

    Facility claims and applicability are subject to member contract provisions which supersede clinical criteria.

    ECOG Performance Status (0–5)
    Scale range0–5 (0 = fully active; 5 = dead).
    ECOG 0 exampleFully active, able to carry on all pre-disease performance without restriction.
    ECOG 2 exampleAmbulatory and capable of all self-care but unable to carry out any work activities; up and about >50% of waking hours.
    ECOG 3 exampleCapable of only limited self-care; confined to bed or chair >50% of waking hours.
    Karnofsky Performance Scale (0–100)
    Scale range0–100 (100 = normal, no evidence of disease; 0 = dead).
    Karnofsky 100–90100 = Normal, no complaints; 90 = Able to carry on normal activity; minor signs or symptoms of disease.
    Karnofsky 70–6070 = Cares for self but unable to carry on normal activity or active work; 60 = Requires occasional assistance but can care for most personal needs.
    Karnofsky 40–1040 = Disabled, requires special care and assistance; 10 = Moribund, rapidly progressing fatal process.
    Documentation Required

    Required Documentation and Benefit Note

    Specific documentation must be provided to support medical necessity, including relevant imaging (CT, MRI, angiography), clinical history, ECOG or Karnofsky performance status, prior treatment records, and operative or pathology reports when applicable. When services are performed in a facility setting, include the required Benefit Applications statement and verify benefits per the member contract.

    • Include imaging reports demonstrating target size and location
    • Document ECOG or Karnofsky performance status and rationale for expected functional change with treatment
    • Include evidence of prior surgery or contraindication to surgery when applicable
    • Attach EEG/MRI concordance and anticonvulsant trial history for epilepsy indications
    Note

    Prior Treatment Expectations

    For certain indications, evidence of prior treatment or trials is required (examples: epilepsy — seizures refractory to at least two anticonvulsant medications with EEG/MRI concordance; trigeminal neuralgia — refractory to medical management; essential tremor — refractory to ≥1 year of standard medication and when deep brain stimulation is not an option). Provide documentation of prior therapies, contraindications, or reasons therapies are not appropriate.

    • Epilepsy: documentation of at least 2 failed anticonvulsant medications and concordant EEG/MRI
    • Trigeminal neuralgia: documentation of failed medical management
    • Essential tremor: documentation of ≥1 year of medication failure and that deep brain stimulation is not an option
    Note

    Contract Precedence and Benefit Verification

    Member contract provisions, restrictions, and exclusions supersede the clinical criteria adopted in this policy. Always verify member benefits and any applicable preauthorization or site-of-service requirements prior to scheduling or performing SRS.

    • If the member contract limits coverage, that limitation prevails even if clinical criteria are met
    • Confirm site-of-service coverage (inpatient vs outpatient vs ASC) as some places require authorization
    ECOG range
    ECOG performance status ranges 0–5 and is referenced for eligibility assessments (examples and cutoffs used in policy).
    Karnofsky rangeKarnofsky Performance Scale ranges 0–100 and is referenced for eligibility assessments (examples and cutoffs used in policy).
    ECOG Performance Status — definition summary
    ECOG scale overview0 = Fully active; 1 = Restricted in strenuous activity but ambulatory; 2 = Ambulatory and capable of self‑care but unable to work (>50% of waking hours up and about); 3 = Limited self‑care, confined to bed/chair >50% of waking hours; 4 = Completely disabled, totally confined to bed/chair; 5 = Dead.
    Use in policyECOG scores are cited as eligibility thresholds (e.g., ECOG ≤3 and expected improvement to ≤2 for brain metastases).
    Karnofsky Performance Scale — definition summary
    Karnofsky scale overview100 = Normal, no complaints; 90 = Able to carry on normal activity; 80 = Normal activity with effort; 70 = Cares for self but unable to work; 60 = Requires occasional assistance; 50 = Requires considerable assistance and frequent medical care; 40 = Disabled, requires special care and assistance; 30 = Severely disabled; 20 = Very sick; 10 = Moribund; 0 = Dead.
    Use in policyKarnofsky cutoffs are used in eligibility (e.g., >40 with expectation to return to ≥70 for brain metastases).
    Clinical revision

    Medically necessary indications revised to add epilepsy and wording of experimental/investigational statement broadened to 'All other uses' (removing the prior specific reference to chronic pain).

    2010-09-08Original approval

    Original Medical Policy Committee approval of the stereotactic radiosurgery using gamma rays policy (MPC approval).